Purpose: To evaluate the relative efficacy of subthreshold micropulse diode laser versus conventional laser photocoagulation for the treatment of diabetic macular edema.
D
iabetic retinopathy is the most frequent and severe ocular complication of diabetes mellitus, the leading cause of blindness in the working-age population in developed countries. 1 Diabetic macular edema (DME) is a major contributor to vision loss and one of the main causes for decreased visual acuity in patients with diabetic retinopathy. 2 The prevalence of DME increases from 0% to 3% in individuals recently diagnosed with diabetes to 28% to 29% in those with a diabetes duration of more than 20 years. 3 The conventional laser (CL) photocoagulation, applied either as a focal or grid pattern and typically using an argon laser (514 nm) or double-frequency Nd-YAG laser (532 nm) was shown by the Early Treatment Diabetic Retinopathy Study to reduce the risk of significant vision loss by 50% and has been the standard of care for DME since the mid-80s. 4 Moreover, focal/grid laser treatment was shown to be more effective and to have fewer side effects compared with two doses of intravitreal triamcinolone in a multicenter randomized clinical trial by the Diabetic Retinopathy Clinical Research Network at both 2-and 3-year follow-ups. 5, 6 However, the beneficial effect of CL is associated with destruction of retinal photoreceptors, progressive enlargement of laser retinal scars (in some cases leading to a foveal atrophy), and development of choroidal neovascularization and subfoveal fibrosis. [7] [8] [9] [10] Moreover, despite the proven benefit in stabilization of central visual acuity, laser photocoagulation for DME invariably results in a localized loss of perimetric sensitivity within 10°eccentricity of the fovea. 7, 11 These complications have been attributed to spread of thermal energy from individual laser burns and collateral damage to adjacent neural retina and choroidal layers with continuous-wave laser therapy.
To reduce this collateral damage, other wavelengths in the infrared part of the spectrum (810 nm), typically delivered by a diode laser, have been introduced in the management of DME. This was supplemented by a different modality for delivery of the laser light such as micropulse laser delivery. 12 In this modality, the laser energy is delivered in short pulses ("micropulses"), typically within a 100-to 300-milliseconds "on" cycle and 1700-to 1900-milliseconds "off" cycle rather than as a continuous wave with hundreds of milliseconds cycle duration as with the CL. The longer "off" interval allows for heat dissipation and confines the energy transfer to the tissue with maximal absorption of laser energy, in this case-the melanocytes within the retinal pigment epithelium. This treatment was named subthreshold micropulse diode laser (SDM) treatment because there is no visible scarring and the individual burns remain below the threshold of observability. Histological studies have indicated that when applying 810-nm laser pulses of microsecond duration, the laser energy affects almost exclusively the retinal pigment epithelium, with very little damage to the overlying neural retina or the underlying choriocapillaris. 13 Therefore, the abovementioned heat-induced complications associated with the conventional continuous-wave laser treatment may be decreased by this type of treatment, which can lead to less negative effects on visual function. However, it may be possible that the smaller amount of laser energy per treatment may not be as effective as in CL mode to reduce macular edema and therefore to decrease central macular thickness (CMT). To the best of our knowledge, there has been no meta-analysis of randomized controlled trials (RCTs) comparing the outcomes of SDM versus CL in patients with DME. Therefore, we undertook a meta-analysis of all available RCTs to assess the efficacy of these two treatments for the management of DME.
Methods
This meta-analysis was performed according to the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) statement. 14 
Search Strategy
We conducted searches of PubMed, ClinicalTrials. gov, and the Cochrane Library using the terms diabetic macular edema or DM and subthreshold micropulse diode laser or SDM. A manual search was performed by checking the reference lists of original reports and review articles to identify studies not yet included in the computerized databases. The final search was performed on October 1, 2015, without restrictions regarding publication year or language.
Inclusion and Exclusion Criteria
Articles were considered eligible for inclusion in the meta-analysis if the studies met the following inclusion criteria: 1) study design: RCT, 2) population: DME without previous treatment, 3) intervention: SDM versus CL, and 4) outcome variables: at least one of the outcomes of interest discussed in the section Outcome Measures below. Abstracts from conferences, full texts without raw data available for retrieval, duplicate publications, letters, and review articles were excluded. When sequential reports on the same cohort of patients were considered, only the most recent report was included, and data that could not be obtained from this last publication were obtained from the previous reports.
Outcome Measures
The primary outcome measure was the mean change in logarithm of the minimal angle of resolution (logMAR) best-corrected visual acuity (BCVA) from baseline. The secondary outcome measure was the mean change in CMT from baseline.
Data Extraction
The data were extracted independently by two reviewers (G.C. and W.L.). Disagreement was resolved by discussion. The information extracted from each study included the authors of each study, the year study was reported, information on the study design, location of the trial, duration of the study, number of subjects, the mean change in BCVA presented as logMAR, and the mean change in CMT measured with optical coherence tomography and presented as change in micrometers of total retinal thickness.
Qualitative Assessment
The qualities of RCTs were assessed by two independent observers (F.J. and S.M.) using a Jadad scale, 15 allocating 1 point for the presence of each of the following: randomization, masking, and participant withdrawals/dropouts. If randomization and blinding were appropriate, 1 additional point was added for each. Thus, the total score ranged from 0 to 5. Studies scoring less than three points were considered to be of low quality.
Statistical Analysis
The quantitative data were entered into the Cochrane Review Manager (RevMan; software version 5.1; Copenhagen, Denmark: The Nordic Cochrane Center, The Cochrane Collaboration, 2011). For continuous variables (e.g., BCVA), the weighted mean difference (WMD) was measured, outcome was reported with a 95% CI. P , 0.05 was considered statistically significant on the test for overall effect. The I 2 statistic was calculated to assess heterogeneity between studies (P , 0.05 was considered representative of significant statistical heterogeneity). 16 If there was heterogeneity between studies, a random-effects model was applied to the data. Alternatively, a fixedeffects model was used for pooling the data. For continuous variables, percent weights were based on SD: smaller SD resulted in greater percent weight. 17 Begg's rank correlation test and Egger's linear regression test were used to quantitatively assess publication bias (P , 0.05 was considered representative of significant statistical publication bias). 18, 19 Results
Overall Characteristics of Selected Trials and Quality Assessment
A total of 48 articles were initially identified. Of these, 42 were rejected according to the exclusion criteria listed above. Hence, a total of six studies were included in this meta-analysis. [20] [21] [22] [23] [24] [25] A flow diagram of the search procedure and results is provided in Figure  1 . One study (Lavinsky et al 22 ) had three treatment groups (CL, normal-density SDM, and high-density SDM). Based on the reported effects on the visual acuity and interpretation of other authors, 26 the highdensity treatment group was selected for this metaanalysis. In total, there were 398 eyes included in this meta-analysis. Of note, 203 eyes were included in the SDM group, and 195 eyes were included in the CL group. All studies fulfilled the quality criteria (three points or more). In all the included studies, no statistical significant differences in the visual acuity were reported between the SDM group and CL group at baseline. The characteristics of the studies included and quality scores are summarized in Table 1 .
Effects on Best-Corrected Visual Acuity
Four studies involving 215 eyes compared SDM with CL in terms of mean change in logMAR BCVA at 3 months and 6 months from baseline and two studies involving 146 eyes reported results at 9 and 12 months. Overall, all results demonstrated good stabilization of visual acuity with both types of treatment. Nevertheless, SDM seemed to be superior to CL in terms of mean change in logMAR BCVA at 3, 9, and 12 months after treatment (WMD = 20.06, 95% CI: 20.12 to 20.01, P = 0.02; WMD = 20.09, 95% CI: 20.17 to 0.00, P = 0.04; and WMD = 20.10, 95% CI: 20.19 to 20.01, P = 0.03, respectively), whereas it showed the same trend but no statistical significance at 6 months (WMD = 20.06, 95% CI: 20.12 to 0.00, P = 0.05), with no heterogeneity identified (Figure 2 ).
Effects on Central Macular Thickness
Four studies involving 215 eyes compared SDM with CL in terms of mean change in CMT at 3 months after treatment, five studies (314 eyes) reported results at 6 months, two studies (146 eyes) at 9 months, and three studies (230 eyes) at 12 months. As with visual acuity, overall, the results showed that both treatments were efficacious in reducing CMT at all follow-up time points. There were no significant difference between SDM and CL in the mean change of CMT at any time after treatment (WMD = 22.52, 95% CI: 221.57 to 16.52, P = 0.80; WMD = 27.68, 95% CI: 219.34 to 3.98, P = 0.20; WMD = 22.60, 95% CI: 237.55 to 32.36, P = 0.88; and WMD = 22.49, 95% CI: 230.44 to 25.46, P = 0.86, respectively), with no heterogeneity identified (Figure 3 ). Begg's rank correlation test and Egger's linear regression test indicated no publication bias for any of the parameters.
Discussion
In this meta-analysis, we reviewed the results from six RCTs, including a total of 398 eyes (203 eyes in the SDM group and 195 eyes in the CL group). In terms of the effect on central visual acuity, both treatment modalities demonstrated good stabilization effect up to 12 months after treatment. Still, although
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none of the studies demonstrated any statistical difference between the two treatments, when aggregated within this meta-analysis, the results from applying SDM treatment seemed to be superior in stabilizing BCVA compared with CL treatment at all time points up to 12 months. Both treatments substantially reduced fluid in or under the retina, and SDM demonstrated equivalent efficacy when compared with CL at all follow-up time points.
Subthreshold micropulse diode laser treatment is based on the principle of applying low energy per single pulse, in an attempt to confine the place of interaction of laser energy with the retina to the retinal pigment epithelium cells and avoid thermal spread to the surrounding tissue. 13 Figueira et al 20 found that less laser scars were detected in the SDM group compared with the CL group. This is an important finding, as spread of retinal atrophy around laser scars produced by a continuous-wave laser occurs over the years and is a frequent complication, particularly for macular laser. 27 Vujosevic et al 24 found that central retinal sensitivity determined by microperimetry was improved after treatment in the SDM group at 12 months, whereas it decreased in the CL group at the same time point. Similarly, Venkatesh et al 23 found that central visual function was better maintained after SDM treatment compared with the results after CL treatment based on multifocal electroretinograpy, likely a result of lesser collateral thermal damage to the neural retina. In the current meta-analysis unexpected adverse effects of both treatment modalities were minimal and theoretically, the less destructive nature of the micropulse approach could explain the better visual acuity outcome despite the comparable decrease in total retinal thickness observed with both treatments at the same time points.
Current treatment options for DME allow for varied and increasingly complex combinations of treatment paradigms such as laser monotherapy, combination of laser therapy with anti-vascular endothelial growth factor (anti-VEGF) agents (RBZ, bevacizumab, and aflibercept), anti-VEGF monotherapy, and sustainedrelease corticosteroid therapy (dexamethasone, either as a monotherapy or in combination with the other therapies). Focal/grid laser as a monotherapy has been the mainstay of treatment of DME until recently when results from RCTs started to indicate that the addition of anti-VEGF therapy may result in better efficacy. This was confirmed in a recent meta-analysis by our group, which indicated that intravitreal ranibizumab combined with laser is more effective compared with laser monotherapy both in terms of BCVA improvement and CMT reduction. 28 As intravitreal drug effects tend to be of rapid onset but relatively brief, whereas laser effects tend to be slower in onset but long-lasting, a combination of intraocular drug delivery and laser may be more beneficial than laser monotherapy or anti-VEGF monotherapy to selected patients with DME, particularly those presenting with severe center-involving DME. As a result of the tissue damage, inflammation and negative effect on the central visual function caused by CL, alternative therapies such as SDM represent a way to provide a better DME treatment in parallel with efforts focused on drug development. The results from the current metaanalysis support this point of view. It is worth noting that despite the inferior efficacy of laser monotherapy (either CL or SDM) compared with other treatments, it remains the only one-time event treatment option and, as such, may still be suitable for some patients who would either refuse intravitreal injections or would be anticipated to have poor compliance in view of the relatively strict treatment regimen associated with intravitreal anti-VEGF treatment. This treatment option also retains some advantage in terms of affordability, a factor especially important in developing countries.
Although the results of our meta-analysis showed a statistically significant effect on BCVA in favor of SDM at 3 and 9 months (P = 0.02, P = 0.04, respectively) and borderline significance at 6 months (P = 0.05), the changes in BCVA were relatively small (a mean difference of 0.06-0.09 logMAR) and thus are of limited clinical significance. Only at the 12-month follow-up did the average change in advantage to This work may have some limitations. First, we cannot fully exclude publication bias. It is possible that some works, especially those published in languages other than English may have been missed. Second, the studies were conducted with small or very small sample sizes. This factor may affect the interpretation of the results. Third, a potential source of heterogeneity is difference in BCVA values at baseline as illustrated in Table 1 , which undoubtedly would have influenced the results from the treatment. For example, the two studies that followed BCVA changes up to 12 months had very different baseline BCVA values in the SDM groups: mean BCVA at the higher end of moderate vision loss of 0.90 logMAR (20/160) in Lavinsky et al 22 and substantially better mean BCVA at the lower end of mild vision loss of 0.21 logMAR (20/32) in Vujosevic et al. 24 Correspondingly, the change in BCVA as a result of treatment was much higher in former study (20.25 logMAR) compared with practically no change in the latter study (0.02 logMAR). Another source of heterogeneity is the slightly different types of lasers used (e.g., argon vs. Nd-YAG within the CL treatment paradigm) and the different ethnic backgrounds of the patients (correlated with a different extent of fundus pigmentation and, therefore, slightly different laser absorption efficacy). Finally, all of the studies included were of relatively short follow-up period of 6 or 12 months after treatment. Thus, RCTs of longer duration and larger sample size are needed to provide more definitive information about the long-term efficacy and safety of both treatment modalities.
In conclusion, based on a limited number of studies available at the present time, the theoretical advantages of the SDM therapy over CL therapy for DME were confirmed in terms of better central visual function 
